Politicskeyboard_arrow_down
Sportskeyboard_arrow_down
Entertainmentkeyboard_arrow_down
Artkeyboard_arrow_down
Foodkeyboard_arrow_down
Browse All

The FDA OK’d AstraZeneca’s Lynparza, the first drug aimed at breast cancer patients with an inherited BRCA mutation